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Abstract: Parkinson’s disease [PD] is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting 1%
of the population over the age of 55. The underlying neuropathology seen in PD is characterised by progressive loss of dopaminergic
neurons in  the substantia  nigra pars  compacta with  the presence  of Lewy bodies. The Lewy  bodies are  composed of aggregates
of α-synuclein. The motor manifestations of PD include a resting tremor, bradykinesia, and muscle rigidity. Currently there is no cure
for PD and motor symptoms are treated with a number of drugs including levodopa [L-dopa]. These drugs do not delay progression
of the disease and often provide only temporary relief. Their use is often accompanied by severe adverse effects. Emerging evidence
from both in vivo and in vitro studies suggests that caffeine may reduce parkinsonian motor symptoms by antagonising the adenosine
A2A  receptor, which is predominately expressed in the basal ganglia. It is hypothesised that caffeine may increase the excitatory
activity in local areas by inhibiting the astrocytic inflammatory processes but evidence remains inconclusive. In addition, the co-
administration of caffeine with currently available PD drugs helps to reduce drug tolerance, suggesting that caffeine may be used as
an adjuvant in treating PD. In conclusion, caffeine may have a wide range of therapeutic effects which are yet to be explored, and
therefore warrants further investigation in randomized clinical trials.
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1. INTRODUCTION
Parkinson’s disease [PD] was named after James Parkinson, an English physician who described it as Shaking Palsy
in 1817 [1]. It is the second most common neurodegenerative disorder after Alzheimer’s Disease [AD], affecting 1% of
population over the age of 55 [2, 3]. Clinical manifestations of PD includes a triad of motor symptoms (bradykinesia,
rigidity, and resting tremor) and a range of neuropsychiatric and autonomic manifestations [4]. The precise aetiology of
PD is unknown but studies have shown it to be multifactorial with an underlying genetic and environmental component.
A number of single gene defects have been identified and these account for only 10% of PD cases; with sporadic forms
accounting for the remaining cases [5]. The underlying neuropathology seen in PD is characterised by progressive loss
of dopaminergic neurons in the substantia nigra pars compacta [SNc] with the presence of Lewy bodies [LBs] and Lewy
neurites [LNs] which are primarily composed of aggregates of alpha-synuclein [α-synuclein] [6].
Emerging data from epidemiological studies suggests that PD is less common in caffeine users compared to the
general population [7, 8]. Furthermore, both in vitro and animal studies indicate that caffeine in low to moderate doses
has neuroprotective effects [9]. Data suggests that caffeine antagonises adenosine A2A  receptors as well as prevents
aggregation of α-synuclein [10]. This literature review aims to explore the neurophysiological effects of caffeine and its
potential role as an adjuvant in the pharmacotherapy of PD.
1.1. Risk Factors
Although the aetiology of PD remains unknown, there are a number of important risk factors that play an important
role in the development of PD.
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1.1.1. Age and Gender
PD mostly affects individuals over the age of 50, although rare exceptions in younger individuals are reported. The
risk of developing PD increases with age due to changes in neuronal circuitry and an increase in inflammatory response
in neurons. Age-related cognitive decline and olfactory dysfunction are changes observed in approximately 80% of
individuals in the early stages of the disease [11 - 13]. Such changes are associated with decreased neuronal density and
cholinergic and serotonergic neurotransmitter concentrations in areas such as the locus coeruleus which may attribute to
loss  of  olfaction [14].  In  addition,  PD is  more  prevalent  in  males  due to  influences  of  genetic,  environmental,  and
physiological factors. For instance, since the farming industry is male-dominated, a higher proportion of male farmers
are likely to be exposed to high levels of pesticides, which may trigger PD-inducing neurotoxicity.
Genomic imprinting inactivates one of the two X-chromosomes in females through methylation. This process may
silence a number of genes involved in the pathogenesis of PD on the X-chromosome, halving the effect of any risk
alleles and thus reducing susceptibility to PD [15, 16]. In addition, higher concentrations of endogenous oestrogen in
females may have neuroprotective effects since endogenous oestrogen prevents neurotoxin build-up and loss of dopam-
inergic neurons in the SNC. This effect is not observed in males since oestrogen levels in healthy males are relatively
lower than in females [17]. Nevertheless, the protective effect of oestrogen diminishes in postmenopausal women, and
their risk of developing PD is then equivalent to males [18].
1.1.2. Family History
Monogenic forms account for less than 5% of cases of PD. Genomic variants in at least seven genes are associated
with both autosomal dominant and autosomal recessive forms of PD. These genes (SNCA, LRRK2, EIF4G1, VPS35,
parkin, PARK2, PINK1 and DJ1/PARK7) are reviewed extensively elsewhere [5, 19].
For instance, α-synuclein (SNCA) is central to both familial and sporadic PD. A number of missense mutations in
SNCA (A30P, E46K, and A53T) increase the tendency of α-synuclein protein to form β-sheets which aggregate and
form LBs [20]. Multiple copies of this mutated gene have been reported in a number of familial cases of PD [21].
1.1.3. Occupational Risks and Head Trauma
Farmers are more likely to be exposed to pesticides, which are linked to neurodegenerative disorders. A number of
pesticides contain neurotoxins such as dipyridylium herbicides that are structurally similar to 1, methyl-4-phenyl-1, 2,
3,  6-tetrahydropyridine  [MPTP],  a  fast  acting  neurotoxin.  Such  herbicides  can  induce  parkinsonian  symptoms  and
predispose individuals to the disease by generating reactive oxygen species which destroy dopaminergic neurons in the
SNc [22, 23]. Moreover, some pesticides are known to inhibit neuronal aldehyde dehydrogenase [ALDH] activity which
increases individual susceptibility to PD, particularly in individuals carrying genetic polymorphisms in ALDH2 [24].
Head  injuries  can  cause  cerebral  haemorrhages.  Chronic  head  injuries  involving  concussion  are  reported  to
predispose  individuals  to  neurodegenerative  disorders,  including  PD  [25,  26].  Concussion  often  leads  to  local
inflammation where pro-inflammatory cytokines cause neuronal cell death and remodelling of the brain parenchyma,
which  is  often  witnessed  in  autopsies  of  Parkinson  diseased  brains  [27].  Moreover,  brain  injury  triggers  astrocyte
activation which leads to neuronal injury and scarring since astrocytes are no longer able to maintain the integrity of the
blood-brain barrier [BBB], thereby allowing toxic molecules to reach the CNS [28].
1.1.4. Lower Levels of Folic Acid
Low levels of folic acid are commonly associated with birth defects. Emerging research on rodents suggests that
low levels of folic acid in diet may increase the risk of developing PD. Evidence shows that folic acid normally reduces
mitochondrial dysfunction and promotes the generation of new mitochondria that may help protect neuronal cell death.
Folate deficiency may lead to greater susceptibility to oxidative damage in mitochondria and apoptosis of dopaminergic
neurons in PD [29]. However, at least one prospective clinical trial failed to identify any link between high folic acid
intake and a reduced risk of development of PD [30].
1.2. Neurophysiology of Basal Ganglia
The basal ganglia [BG] are comprised of a number of nuclei in the subcortical region. They play important roles in
the initiation of muscular movements, learning, cognition, and help to coordinate changes in posture. They are comp-
rised  of  a  number  of  structures,  which  includes  the  substantia  nigra  -  a  midbrain  structure  consisting  of  the  pars
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compacta [SNc] and pars reticulate [SNr]. The SNc plays an important role within the basal ganglia in synthesising and
secreting  dopamine  which  binds  to  Dopamine-1  receptors  [D1R]  in  the  BG  [31].  This  subsequently  activates
GABAergic neurons favouring direct pathways, thus facilitating movement [32]. When dopamine binds to Dopamine-2
receptors  [D2R],  indirect  pathways  are  activated  which  subsequently  decreases  thalamo-cortical  firing  and  inhibits
movement as illustrated in Fig (1). The striatum also projects into a number of areas which includes the GPi (contains
GABAergic output neurons), the thalamic nucleus, reticular formation (affects muscle tone), and superior colliculus
(affects eye movements). Alteration in these systems can be observed in PD patients, along with the bradykinesia which
is a result of depletion of dopaminergic neurons in these pathways [32].
Fig. (1). Direct and indirect pathways of Basal Ganglia in initiating motor activity. In the direct pathway, cerebral cortical input to
the striatum causes activation of inhibitory neurons in the striatum which then causes an increased inhibitory output to the globus
pallidus internal [GPi]. There is a decreased inhibitory output from GPi to ventral anterior [VA] and ventral lateral [VL] nuclei of the
thalamus which then projects via excitatory pathways into the premotor cortex. The direct pathway is involved in regulating tonic
excitation in the premotor cortex which is an area involved in planning and initiating movement. The indirect pathway is inhibitory to
movement when excitatory projection from cerebral cortex facilitates inhibitory projection neurons in globus pallidus external [GPe].
These  then  inhibit  tonic  inhibitory  output  neurons  which  decreases  tonic  inhibition  of  subthalamic  nucleus  [STN]  resulting  in
increased excitatory output to GPi. Excitatory input to GPi increases inhibitory output from GPi to thalamus which then decreases
excitatory feedback to cerebral cortex leading to inhibition of motor activity. Dopamine promotes action of direct pathway while
suppressing the activity of indirect pathway.
1.3. Pathophysiology of PD
PD occurs when the activity of neurons in GPe is reduced. This results in an increased discharge of STN neurons.
The degeneration of dopaminergic SNC neurons leads to increased activity of the indirect pathway which causes an
oscillation  in  electrical  discharge  to  neighbouring  neurons  affecting  the  overall  activity  throughout  the  BG  [34].
Pathological changes in basal ganglia results in the development of a resting tremor, loss of coordination, bradykinesia
and postural changes. Rigidity is a product of dopaminergic neuron destruction in SNc which leads the striatum to over
stimulate the corticospinal motor system [33, 34].
1.3.1. Molecular Histopathology of PD
The  accumulation  of  LBs  and  LNs  in  neurons  is  a  characteristic  histological  finding  in  PD.  LBs  and  LNs  are
aggregates  of  α-synuclein,  parkin,  and  synphilin-1  proteins.  α-synuclein  is  found  predominantly  in  the  brain  and
expressed in mitochondria of the striatal and thalamic neurons [35, 36]. The precise role of α-synuclein is not known
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but a number of studies suggest that α-synuclein helps to regulate dopamine release and supply synaptic vesicles to
presynaptic terminals [37]. A number if missense mutations in the α-synuclein gene (A53T, A30P, and E46K) allow the
α-synuclein protein to form aggregates of β-sheets which then form toxic oligomers commonly observed in hereditary
forms of PD [38, 39]. Mutated forms of α-synuclein may have prion protein-like characteristics since it can induce β-
confirmation in normal α-synuclein proteins. It does so by acting as a template to promote misfolding and aggregation
of normal α-synuclein which can then spread on to other regions of the brain [40]. In addition, LBs and LNs have also
been  reported  in  striatal  and  nigral  neurons  of  individuals  who  have  undergone  fetal-nigral  mesencephalic  cell
transplantation [FNMCT], further supporting the hypothesis of prion protein-like characteristic of mutated α-synuclein
[40]. Long-term accumulation of mutant α-synuclein protein also leads to dementia and behavioural as well as cognitive
impairment. These are characteristic features of late stages in PD [41]. In addition to α-synuclein protein, defects in the
parkin gene which produces mutated ubiquitin ligase prevents removal of α-synuclein aggregates, and allows LBs and
LNs to form [42]. Recently, studies reported observing ferric deposition in parkinsonian brains. It was postulated that
high level of iron present in SNc may induced oxidative stress which then leads to loss of dopaminergic neurons [43].
2. NEUROPROTECTIVE AGENTS
Neuroprotection  refers  to  the  preservation  of  neuronal  structure  and  function.  Neuronal  integrity  can  be
compromised in diseases such as PD, and the aim of neuroprotective agents is to protect or slow down the progression
of  disease  by  delaying  the  process  of  neuronal  loss.  There  are  a  number  of  candidates  which  help  to  reduce
neurotoxicity by inhibiting neurotoxins, ROS, preserving mitochondrial function and preventing protein aggregations
[44]. Neuroprotective agents include the following:
2.1. Polyphenols
Polyphenols are naturally occurring compounds found in plants that are responsible for protecting them against
UVB radiation.  Polyphenols have antioxidant and anti-carcinogenic effects  which are yet  to be explored and could
potentially be used to treat a number of degenerative diseases including PD. In addition, polyphenols found in black tea
are  reported  to  inhibit  α-synuclein  aggregation  and  degeneration  of  dopaminergic  neurons  through  an  unknown
mechanism  [45].
2.2. Nicotine
Nicotine is a constituent of cigarettes and is a known potent parasympathomimetic alkaloid that acts on nicotinic
acetylcholine  receptors  [nAchR]  found  in  brain.  Nicotine  can  protect  nigrostriatal  damage  and  help  to  improve
cognitive  functions  according to  a  number  of  randomized controlled  trials  [46].  The  exact  mechanism of  action  of
nicotine in nigtrostiatal pathways remains unknown but some studies suggest that nicotine binds to nAchR and activates
intracellular  transduction,  altering  calcium  signalling  which  may  help  reduce  neuronal  injuries  [46].  In  addition,
nicotine has been found to reduce L-dopa-induced dyskinesia [LID] in a number of animal studies but not in humans
[47].
2.3. Curcumin
Curcumin is an active ingredient of turmeric. It is non-toxic and able to cross the BBB. Curcumin is capable of
binding to mutant α-synuclein, thereby preventing β-aggregation [48, 49]. In doing so curcumin can help reduce LBs
formation  and  reduce  risk  of  developing  PD.  Its  precise  mechanism of  action  is  not  known  but  some  suggest  that
curcumin acts as an amyloid breaker with anti-inflammatory effects in which it is able to reduce generation of ROS
[50].
2.4. Caffeine
Caffeine 3,7-trimethylpurine-2,6-dione is a psychoactive methylxanthine extracted mainly from plant sources. It is
found in a number of beverages such as coffee and tea [51]. 87% of caffeine is consumed in coffee, soft drinks and tea
with  an  average  consumption  of  193mg of  caffeine  per  day  1.2mg caffeine  per  kg  of  body per  day  [52].  Men and
women aged 35-64 were reported to be the highest caffeine consumers [52]. Caffeine is a potent neurostimulant and
also  has  neuroprotective  effects.  Its  effects  on  the  CNS  arise  through  the  competitive  non-selective  inhibition  of
adenosine A1 and A2A receptors. Epidemiological studies suggest that consumption of 3-4 cups of coffee daily (~200mg)
can reduce the risk of PD [53, 54].
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This is further supported by randomized trials and in-vitro  studies that highlight caffeine’s ability to antagonise
adenosine receptors, in particular A2A receptors found in striatopallidal neurons. Blockade of A2A receptors improves
mobility in PD patients [55, 56].
Blockade  of  adenosine  receptors  improves  motor  functions  of  PD  marginally  in  both  animals  and  humans.
Moreover, long-term exposure to caffeine in hemiparkinsonian mice may alter L-dopa responses in PD via unknown
mechanisms [57].  The  benefits  of  caffeine  and its  use  in  adjuvant  therapy are  outlined  in  the  rest  of  this  literature
review.
3. DIFFERENT EFFECTS OF CAFFEINE IN PD
3.1. Adenosine A2A Receptors
Adenosine A2A receptors are distributed in the BG, which is heavily innervated by dopaminergic neurons. Adeno-
sine is a ligand for all adenosine receptors and at low concentrations it shows a greater affinity for A1 receptors where it
decreases  glutamate  release  from  striatal  neurons.  At  high  concentrations,  adenosine  has  a  higher  affinity  for  A2A
receptors and exerts excitatory effects through stimulation of glutamate and Ach release in the striatum. Activation of
adenosine A2A receptors also enhances GABA-A mediated inhibitory effects on the GPe [58].
Adenosine A2A receptors are primarily expressed on striatopallidal neurons and form functional heteromeric compl-
exes with D2 receptors and metabotropic glutamate receptors [mGLU5]. In so doing, A2A receptors can control functions
of indirect  efferent  pathways of the BG. It  is  important  to note that  A2A  receptors are functionally equivalent  to D2
receptors since they form heteromers with D2 receptors by interacting with the arginine-rich domain on D2 receptors. A
similar interaction is also seen between D1-NMDA receptors [N-methyl-D-aspartate receptors] heteromerisation [59,
60] .Upon forming a heteromeric complex with D2 receptors, A2A and D2 receptors become reciprocal antagonists and
form  the  basis  of  motor  control,  learning,  motivation,  and  reward  systems.  D2  receptors  normally  antagonise  A2A
receptors’ activity by inhibiting adenylyl cyclase activation. However, when D2 receptor interacts with A2A receptor in
heteromeric configuration, A2A receptor can reduce the binding affinity of dopamine to D2 receptor, preventing inhi-
bition of motor activity [60]. In addition, co-stimulation of A2A with mGLU5 enhances A2A receptors ability to inhibit D2
receptors  as  well  as  to  override  the  inhibitory  tone  imposed  by  endogenous  dopamine  via  D2  receptors  [61].  The
underlying antagonistic properties of A2A receptor on D2 receptors with deficits in dopamine levels translates to akinesia,
which  is  commonly  seen  in  PD  [61].  Moreover,  loss  of  striatal  dopamine  in  PD  results  in  unopposed  adenosine
stimulation resulting in hyperactivity of indirect pathway and motor dysfunction, which are also features observed in
PD.
3.1.1. Caffeine as an Adenosine A2A Receptor Antagonist
Caffeine is a potent neurostimulant and might protect against a number of neurodegenerative disease and may affect
cell  cycle  function in  certain  types of  cancer  [62,  63].  Nevertheless,  the role  of  caffeine in  cardiovascular  diseases
remains inconclusive according to a prospective cohort study [64]. Emerging evidence from in vivo and in vitro studies
suggests  that  caffeine  may  protect  against  development  of  PD  by  keeping  the  BBB  intact,  which  is  essential  for
neuronal survival and CNS functioning [65, 66]. In addition, caffeine may improve motor functions in PD patients by
modulating adenosine A2A receptors at different dosages [10]. Caffeine is structurally similar to adenosine and is a non-
selective antagonist at A1, A2A, A2B and A3 adenosine receptor subtypes [67]. A2A receptors are predominately found on
striatopallidal  neurons and are antagonised by caffeine,  which results  in decreased intracellular  cAMP levels  and a
diminished release of GABA in the GP [67]. A2A antagonists like caffeine thus may decrease the release of inhibitory
neurotransmitters [GABA] and increases excitatory activity [serotonin, noradrenaline] in the striatopallidal neurons by
stimulation of dopamine D1 and D2 receptors, promoting motor activities in rats [68]. Nevertheless, rapid tolerance to
the effects of caffeine develops in long-term use [69]. Animal studies by Popoli et al. suggests that chronic caffeine
administration combined with a selective A2A receptor antagonist such as SCH 58261 results in less tolerance towards
adenosine A2A receptor antagonists compared to when adenosine A2A receptor antagonists are administered on their own
[70].
Several  studies  have  reported  a  reduction  in  MPTP-induced  destruction  of  dopaminergic  neurons  in  mice
administered with oral A2A receptor antagonists. This protected against the loss of nigral dopaminergic neuronal cells
induced  by  6-hydroxydopamine  in  mice.  A2A  antagonists  also  prevented  the  functional  loss  of  dopaminergic  nerve
Potential Role of Caffeine in the Treatment of Parkinson’s Disease The Open Neurology Journal, 2016, Volume 10   47
terminals  in  the  striatum  and  the  ensuing  gliosis  caused  by  MPTP  in  mice  [71].  The  mechanism  underlying  the
neuroprotective effects of A2A antagonists such as caffeine is still not fully understood.
On the contrary, some studies have reported that the activation of A2A receptors may protect tissues from reperfusion
injury since A2A receptors can inhibit release of pro-inflammatory cytokines [TNF-α, IL-6, IL-8 and IL-12] and increase
the release of anti-inflammatory cytokines such as IL-10 [72 - 74]. Moreover, A2A receptor activation can reduce the
release of a number of ROS from neutrophils and also reduces neutrophilic infiltration into endothelial cells.
In light of the contradictory findings reported in the literature, further evaluation of the role that A2A activation and
antagonism plays in neuroprotection is needed.
3.2. Astrocytes and Their Role in PD
Aside from being an A2A antagonist, caffeine may help stabilise the blood-brain barrier by regulating astrocytes and
inflammatory processes in animal models [66].  Astrocytes are glial  cells found in the mammalian brain that play a
pivotal role in maintaining various neuronal functions by transporting nutrients and metabolites to neurons through a
number of transporters such as the malate-aspartate shuttle. There are two types of astrocytes found in substantia nigra:
[75].
Protoplasmic astrocytes which encapsulate neuronal bodies and synapses1.
Fibrous astrocytes which interact with oligodendroglia and node of Ranvier2.
Research on astrocytes in mice has suggested that α-synuclein affects only protoplasmic astrocytes but not fibrous
astrocytes [76].
Astrocytes are significant players in the central nervous system as they develop and maintain the BBB and promote
neurovascular coupling. One extreme of astrocytes faces endothelial cells to maintain BBB and control cerebral blood
flow [CBF] while the other extreme is in communication with numerous neurons [77]. Moreover, astrocytes can release
chemokines, gliotransmitters and help in the uptake of glutamate and GABA from the synaptic cleft. Other functions of
astrocytes include pH regulation, K+ buffering, metabolising dopamine, and producing antioxidants such as gluthathione
[GSH] and superoxide dismutases [SOD 1, and 2] [78].
In neurodegenerative diseases such as PD, astrocyte functions are compromised. Neurons are more susceptible to
injury due to their limited capacity to counteract free radical-induced damage. Furthermore, neurons require a number
of nerve growth factors [NGF] which are derived from astrocytes [79]. In the absence of astrocytes, neuronal functions
are compromised and cell death slowly ensues during brain degeneration in PD [79]. In addition, during the process of
reactive astrogliosis in the substantia nigra [an abnormal increase in astrocyte numbers secondary to neuronal death],
astrocytes release a number of proinflammatory cytokines that act on neighbouring neurons. The increased production
of  ROS  and  activation  of  apoptotic  mechanisms  is  often  observed  in  PD,  and  may  lead  to  death  of  dopaminergic
neurons. Reactive astrogliosis is one of the main features seen in astrocytes following brain injuries, and in neurodeg-
enerative  diseases  caused  by  trauma,  α-synuclein  aggregation,  and  ischemia  [79].  A  number  of  researchers  have
suggested  that  neurotoxins  such  as  MPTP  are  capable  of  inducing  astrogliosis  and  microgliosis  which  are  often
accompanied by mitochondrial dysfunction, nuclear karyolysis, and eventually neuronal death [80].
It is widely reported in a number of animal studies that astrocytes actively participate in the death of dopaminergic
neurons by activating apoptosis through cytokines [TNFα, IL-1B and IL-6] and nitric oxide [NO] [28]. NO is believed
to promote the release of cytochrome C from dysfunctional mitochondria while cytokines bind to specific receptors in
dopaminergic neurons to activate the pro-apoptotic caspase pathway [81, 82]. Oxidative damage is a common feature
observed  in  PD  brain  samples  [83].  The  increased  uptake  of  α-synuclein  by  astrocytes  leads  to  up-regulation  of
inflammatory  molecules  causing  further  production  of  ROS  which  may  then  lead  to  DNA  damage  [84].  Further
depletion of GSH and SOD 1 and 2 may facilitate production of ROS and reactive nitrogen species [RNS] in astrocytes.
This then leads to structural alteration and aggregation of normal α-synuclein proteins [85, 86]. Recent findings in mice
models  of  PD have found that  the  nitration (nitrogen group is  introduced to  tyrosine  residue on α-synuclein)  of  α-
synuclein induced by oxidative injury (activation of induced nitric oxide synthase [iNOS] and focal adhesion kinase
[FAK])  can  enhance  α-synuclein  fibril  formation  causing  cell  death  [87,  88].  Therefore  one  may  conclude  that
inhibiting  glial  inflammatory  processes  could  reduce  neuronal  damage  during  PD  [89].
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3.2.1. Caffeine Inhibits Astrocyte-induced Inflammation in PD
Even  though  caffeine  can  antagonise  all  forms  of  adenosine  receptors  it  remains  ineffective  in  antagonising
purinergic-7 receptors [P2X7R] which are ligand-gated cation channels that open in response to ATP binding and lead
to cell depolarization. P2X7 receptors are present on neurons and astrocytes throughout the CNS and PNS [90]. Recent
studies  suggest  that  P2X7R  mediates  platelet  aggregation  as  well  as  microglial  activation  during  inflammation.
Moreover, P2X7R are also responsible for mediating apoptosis [91]. The use of a P2X7R antagonist, in combination
with an adenosine receptor antagonist such as caffeine may reduce the inflammatory processes that are triggered by
both receptors and their subtypes [92].
In addition, a number of studies in newborn rat brain cultures suggest that high doses of caffeine can reduce glial
cell proliferation. This may be useful in reducing the inflammatory process in PD brains [93]. By actively preventing
glial cell proliferation, specifically astroglyosis, the progression of neurodegeneration may be stalled due to mecha-
nisms that prevent the breakdown of the BBB and the excessive release of gliotransmitters such as glutamate that lead
to neurotoxicity.
Caffeine is also reported to suppress the production of TNF-α through protein kinase A dependent mechanisms in
human blood according  to  Horrigan  et  al.  [94].  Furthermore,  caffeine  is  reported  to  mediate  glutathione  synthesis,
reducing the ROS and RNS induced inflammatory response in the hippocampus of rodents leading to neuroprotection
[95].
Astrocytes also express adenosine A2A receptors that may be antagonised by adenosine A2A antagonists, favouring
the increased uptake of glutamate into astrocytes and thus reducing glutamate levels  at  the synaptic cleft.  This can
reduce the incidence of neurotoxicity induced by the excessive stimulatory effects of neurotransmitters [95, 96]. In
addition to increased gliotransmitter uptake, chronic caffeine intake in non-habitual caffeine consumers may reduce
CBF acutely through an unknown mechanism, which may involve vasoconstriction of cerebral vessels [97, 98].
3.3. Overexpression of Cav 1.3 Ca
2+ Channels and Inhibition by Caffeine in PD
Voltage-gated calcium channels 1.3 [Cav 1.3 Ca
2+] are L-type calcium channels that are selectively permeable to
calcium ions. Cav 1.3 Ca
2+ channels have an α1 subunit which is a prime target for calcium-channel blockers such as the
dihydropyridines [99]. In addition to astrocyte dysregulation, the activity of Cav 1.3 Ca
2+ channels has been implicated
in the neurodegeneration of dopamine-producing neurons in PD. Dopaminergic neurons found in SNc  continuously
generate low frequency basal activity using Cav 1.3 Ca
2+ channels. These L-type calcium channels have low expression
levels  [100].  Other  L-type  calcium  channels  found  in  SNc  include  Cav  1.2  Ca
2+  channels.  These  are  exclusively
expressed in dopaminergic neurons located in the SNc and are only activated at higher membrane potentials. Conversely,
Cav  1.3  Ca
2+  channels  are  activated  at  sub-threshold  membrane  potentials,  making  them  ideal  pacemaker  cells  in
neurons.  However,  they  require  significantly  more  ATP  to  sustain  their  transient  activity.  Moreover,  Cav  1.3  Ca
2+
channels  generate  oxidative  stress  mediated  by  mitochondria  during  periods  of  pacemaker  activity  via  unknown
mechanisms [101].
Recent studies suggest that there is an increased density of Cav 1.3 Ca
2+ channels in dopaminergic neurons in mice
models of PD [102]. The increased expression of dopaminergic neurons in Cav 1.3 Ca
2+ channels generates more ROS
that leads to neurodegeneration of dopaminergic neurons as seen in PD. These changes in the expression of voltage
gated calcium channel subtypes in PD are of particular therapeutic interest [102]. A number of studies have reported the
potential  benefits  of  dihydropyridine  [DHP]  calcium  channel  blockers  in  reducing  pathogenesis  of  PD  as  well  as
mortality in elderly PD patients [103]. Other studies have reported that caffeine can inhibit ryanodine receptors [RyRs]
in certain parts of the body [104]. RyRs play a central role in microglial-mediated inflammation, and are believed to
contribute to pathogenesis of neurodegenerative disorders such as PD. Inhibition of RyRs shows therapeutic promise in
the management of PD [105]. Studies have also shown that protein kinase C [PKC] activation may lead to phospho-
rylation  of  serine  residue  81  on  the  amino-terminus  of  Cav  1.3  Ca
2+  channels,  leading  to  their  inactivation  [106].
However, no studies have reported possible effects of caffeine on protein kinase C pathways in the CNS or on inhibition
of Cav1.3 Ca
2+ channels.
3.4. Efficacy of Caffeine in Different People and Genders
Caffeine may show promise in the pharamcotherapy of PD since it antagonises adenosine receptors, inhibits the
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inflammatory  response,  and  possibly  inactivates  calcium channels.  The  effect  of  caffeine  was  reported  to  be  dose-
dependent in a randomised controlled trial showing that a daily dose of 100-200mg of caffeine can reduce the risk of
PD  motor  symptoms,  while  a  daily  dose  of  above  200mg  caffeine  was  ineffective  [107].  The  reason  behind  this
discrepancy includes genetic variation and gender differences. Genetic variation in cytochrome CYP1A2 gives rise to
fast and slow metabolisers of caffeine. CYP1A2 is a primary enzyme responsible for metabolism of 95% of caffeine into
three active metabolites: paraxanthine, theophylline, and theobromine. Each of these metabolites exert different effects.
Certain variations in CYP1A2 gene result in a reduced ability to metabolise caffeine slow metabolisers [108]. These
individuals are prone to hypertension as high levels of caffeine in serum can activate systemic epinephrine release.
Moreover,  sustained  hypertension  leads  to  vascular  disease  and  possibly  early  myocardial  infarction  and  cerebro-
vascular accidents, that may then induce secondary neurodegenerative disorders such as vascular parkinsonism [109,
110].
Conversely, fast metabolisers overexpress CYP1A2. This results in rapid and efficient metabolism of caffeine [108].
These individuals may require higher doses of caffeine in order to achieve the same therapeutic effects of caffeine in
reducing the prevalence of PD. However, conflicting studies have suggested that slow metabolisers are not necessarily
at higher risk of developing PD when compared to fast metabolisers and this warrants further long-term clinical trials
[108].
Apart from variation in caffeine metabolism, gender may also account for differences in the incidence of PD and
response to caffeine. PD is more prevalent in males than in females due to differences in physiological adaptation as
well as differences in toxicant exposure rate [111]. Nevertheless, in a number of epidemiological studies, it is reported
that male caffeine users were more likely to have lower incidence of PD compared to female caffeine users. This lead to
a number of large prospective studies which highlighted the possible link between exogenous oestrogen in Hormone
Replacement Therapy [HRT] and reduced efficacy in postmenopausal women with higher PD incidence [112, 113]. It
seems that exogenous oestrogen present in HRT reduces half-life of caffeine similar to those seen in fast metabolisers of
caffeine,  suggesting  that  exogenous  oestrogen  may  put  females  on  HRT  at  a  greater  risk  of  developing  neurode-
generative  diseases  such  as  PD.  In  vitro  animal  studies  have  compared  the  effects  of  a  20mg  caffeine  dose
administration in normal vs  ovariectomised mice exposed to MPTP. Ovariectomised mice had reduced parkisonian
symptoms compared to normal mice. In addition, when male mice were injected with exogenous oestrogen and MPTP,
they  showed  the  same  parkinsonian  symptoms  as  female  mice  with  ovaries.  This  suggests  that  administration  of
exogenous oestrogen may somehow inhibit the neuroprotective effects of caffeine [114, 115].
3.5. Caffeine as an Adjuvant Therapy in PD
The evidence outlined above highlights a number of beneficial effects of caffeine that could possibly justify its use
as an adjuvant drug in the management of PD. There are reported experimental uses of caffeine in treating PD. For
instance, trihexyphenidyl [THP] is an anti-parkinsonian agent that has been clinically used to treat PD [116]. It is a
potent M1 receptor antagonist that inhibits M1 receptors in different parts of the cerebral cortex. Its use is accompanied
by side effects that include memory impairment [116]. When THP is co-administered with low doses of caffeine in
mice,  there  is  increased  THP  potency  without  memory  impairment.  Observational  studies  on  reserpine-induced
hypokinesia  in  rats  reported  no  reversal  of  symptoms  when  caffeine  or  THP  were  used  on  their  own  [117,  118].
Conversely, when caffeine and THP were co-administered, they restored locomotion in reserpine-treated rats.
The authors concluded that low doses of caffeine co-administered with THP might help reduce a number of motor
deficiencies in animals, which are seen in PD. Nevertheless, long-term randomized clinical trials are needed to assess
such claims and therapeutic benefits of such co-administration [116].
Other  studies  have  investigated  the  effects  of  caffeine  co-administration  with  bromocriptine.  This  improves  a
number of motor functions in rats under an observational study. Bromocriptine is a dopamine agonist commonly used to
treat  PD.  When  Bromocriptine  is  administered  individually  in  denervated  rats,  subthreshold  motor  activities  were
recorded [119, 120]. When Bromocriptine was co-administered with caffeine, levels of motor activity were slightly
higher than with the isolated use of Bromocriptine. Nonetheless, tolerance to caffeine was reported in rats administered
only caffeine for a significant period of time but no tolerance to Bromocriptine was reported. In addition, no tolerance
to chronic use of caffeine was reported when it was co-administered with Bromocriptine, and sustained levels of motor
activity was observed in these rats [120]. Therefore, it is important to explore the relationship between caffeine and
other parkinsonian drugs to determine the underlying mechanisms that allow caffeine to enhance efficacy and reduce
drug tolerance [120].
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A number of novel approaches have been adopted by the scientific community in an attempt to find better and more
efficacious treatment for PD. Currently, Parkinsonian symptoms are treated through medications such as L-dopa and
dopamine agonists like pramipexole and rotigotine, which themselves are accompanied by significant side effects that
range from hypotension to gastrointestinal disturbances [121, 122] . Moreover, most of these drugs undergo first pass
metabolism through the liver and are metabolised by circulating enzymes such as Monoamine oxidases [MAO] which
reduces their bioavailability in the body. Hence they do not offer a long-term solution in treating PD.
In summary, caffeine is a cheap and widely-available neuromodulator which can be used in the treatment of PD in
conjunction  with  current  therapy.  Nevertheless  the  precise  dosage  and  safety  of  caffeine  is  of  particular  concern
especially when it is administered at high doses for a significant period of time; a number of adverse effects such as
resting tremors have been reported in chronic caffeine users. Therefore, more long-term double-blinded randomized
controlled  trials  in  humans are  necessary  in  order  to  evaluate  the  efficacy and possible  uses  of  caffeine  in  treating
conditions like PD.
CONCLUSION
It  was  not  until  recently  that  the  scientific  community  began  to  notice  the  neuroprotective  effects  of  caffeine
following the  observation  of  lower  incidences  of  PD reported  in  chronic  caffeine  users.  Recent  animal  and human
studies  have  suggested  that  caffeine  may  help  to  treat  PD since  it  can  antagonise  the  adenosine  A2A  receptors  and
inflammatory changes in the BG. Moreover, caffeine can prevent apoptotic cell death by lowering caspase-3 activity
that is induced by neurotoxins such as MPP+, as well as decrease the number of apoptotic fragmented nuclei. In doing
so it may halt dopaminergic neuronal destruction and act as cytoprotective agent [123].
As a result, caffeine might be able to prevent neurotoxicity induced by LBs and LNs. The beneficial functions of
caffeine may not be limited solely to neuronal cells as it may be able to decrease the activity and proliferation of non-
neuronal  cells  like  astrocytes,  which  are  primary  regulators  of  the  BBB  and  produce  a  number  of  inflammatory
molecules in early and late stages of PD. Further randomised trials are needed to support this hypothesis.
The  physiological  role  of  caffeine  may  also  help  reduce  the  incidence  of  drug  tolerance  that  often  develops  in
advanced stages of PD where patients are given higher dosage to achieve the same therapeutic effects. Nevertheless, the
beneficial effects of caffeine are not observed in all individuals due to genetic and gender differences. Individuals with
variants in CYP1A2 are known to metabolise caffeine at a much slower rate than normal, this potentially predisposes
them to cardiovascular diseases.
Aside for genetic variation, gender difference may also limit the neuroprotective effects of caffeine since females on
HRT  are  not  protected  from  neurodegenerative  diseases  even  when  caffeine  is  consumed  chronically  [124].
Physiological  studies  have  suggested  that  exogenous  oestrogen  in  HRT  may  inactivate  neuroprotective  effects  of
caffeine which may predispose females on HRT at higher risk of developing neurodegenerative disorders like PD [115].
In addition, most studies are currently conducted on animals, and may not have similar effects in humans.
Furthermore  there  is  no  single  universally  agreed  dosage  of  caffeine  which  has  been  agreed  by  the  scientific
community. Doses used in most studies varied from 20mg to over 200mg [107, 125]. Moreover, long-term double-
blinded  randomised  trials  are  needed  to  show  the  correlation  between  caffeine  usage  and  low  incidence  of  PD.
Nonetheless, caffeine remains an interesting area of active research and may one day prove to be a cheap alternative to
current PD treatment. In addition, a number of caffeine analogues are under investigation in clinical trials and have
shown some promising results. Therefore, it is not long before caffeine will be used as an adjuvant therapy in treating
neurodegenerative diseases like PD.
LIST OF ABBREVIATIONS
α-synuclein = Alpha-synuclein
A2AR = Adenosine A2A Receptor
Ach = Acetylcholine
AMP = Adenosine Monophosphate
APOE gene = Apolipoprotein E gene
ATP = Adenosine Triphosphate
BBB = Blood-Brain Barrier
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BG = Basal ganglia
cAMP = Cyclic Adenosine Monophosphate
Cav 1.3 Ca
2+ = Voltage gated Calcium channels 1.3
CBF = Cerebral blood flow
CNS = Central nervous system
CYP1A2 = Cytochrome-P450 1A2
D1/D2R = Dopamine-1/Dopamine-2 reeceptors
DHP = Dihydropyrindine
ETC = Electron transport chain
GABA = Gamma-aminobutyric acid
GPi = Globus pallidus internal
GPe = Globus pallidus external
Gsα = G-protein α- stimulatory subunit
Giα = G-protein α-inhibitory subunit
HRT = Hormone replacement therapy
IL-6/IL-8 = Interleukins-6/Interleukins-8
IL10/IL-12 = Interleukin-10/Interleukins-12
LBs/ LNs = Lewy bodies/ Lewy neurites
L-dopa = Levodopa
LID = L-Dopa induced dyskinesia
M1R = Muscarinic-1 Receptor
MAO = Monoamine oxidases
mGLU5 = Metabotropic glutamate-5 receptors
MRI = Magnetic Resonance Imaging
MPP+ = 1-methyl-4-propionoxypiperidine
MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
nAchR = Nicotinic Acetylcholine Receptors
NGF = Nerve growth factors
NMDA = N-methyl-D-aspartate receptor
NO = Nitric Oxide
PD = Parkinson’s disease
PGE-2 = Prostaglandin-E2
PINK-1 = PTEN induced kinase-1
PKC = Protein kinase C
PNS = Peripheral nervous system
P2X7R = Purinergic-7-receptors
RNS = Reactive nitrogen species
ROS = Reactive Oxygen Species
SNc = Substantia nigra pars compacta
STN = Subthalamic nucleus
SNr = Substantia Nigra pars reticulata
TNF-α = Tumour necrosis factor-alpha
THP = Trihexyphenidyl
UVB = Ultraviolet-B
VA = Ventral anterior
VL = Ventral lateral
X-chromosomes = Sex chromosomes
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